Health Care & Life Sciences » Biotechnology | Can-Fite Biopharma Ltd.

Can-Fite Biopharma Ltd.

Can-Fite Biopharma Ltd. ADR
Stock Exchange NYSE
EPS
$4.83
Market Cap
$9.7 M
Shares Outstanding
3.32 M
Public Float
-

Profile

Address
Kiryat Matalon
Petach Tikva TA 4951778
Israel
Employees -
Website http://www.canfite.com
Updated 07/08/2019
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer.

Financials

View All
Created with Highcharts 5.0.14Can-Fite Biopharma Ltd. ADRNet Income. Fiscal year is January-December. All values ILS Thousands.29 04929 04923 75923 75918 72618 72626 53226 53217 26917 26923 62423 62420132014201520162017201805k10k15k20k25k30k35k
Created with Highcharts 5.0.14Can-Fite Biopharma Ltd. ADRSales/Revenue. Fiscal year is January-December. All values ILS Thousands.00006436436526522 9362 93613 73313 73320132014201520162017201802.5k5k7.5k10k12.5k15k

Ilan Cohn
Chairman
Pnina Fishman
Chief Executive Officer & Director